Not Just Drugs and Vaccines: Kalbe Farma's Expansion Strategy

Healthcare issuer PT Kalbe Farma Tbk (KLBF) recorded a 10.1% year-on-year revenue growth in the first quarter of 2026, reaching Rp 9.68 trillion. Director of PT Kalbe Farma Tbk, Mulia Lie, stated that the positive performance amidst global turmoil was inseparable from the company’s sustainable healthcare ecosystem. Increasing public awareness of maintaining health and improvements in healthcare services and infrastructure have become pillars supporting economic growth, including the health sector. Kalbe Farma, in its role supporting efforts to improve the quality of public health in Indonesia, is committed to developing healthcare products not only for curative treatment but also for preventive and promotive care, with health foods and multivitamins being among the segments that continue to grow within the company.